UBS Initiates Coverage On ShockWave Medical with Neutral Rating, Announces Price Target of $218
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy has initiated coverage on ShockWave Medical (NASDAQ:SWAV) with a Neutral rating and a price target of $218.

September 29, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS has initiated coverage on ShockWave Medical with a Neutral rating and a price target of $218.
The initiation of coverage by UBS with a Neutral rating suggests that the analyst sees the stock as fairly valued at current levels. The price target of $218 indicates where the analyst believes the stock will trade in the near term. This could influence investor sentiment and potentially impact the stock's price, but the neutral rating suggests no significant upward or downward movement is expected in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100